Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

We recently published a list of Jeff Smith’s Top 10 Activist Targets and Their Returns Compared to the S&P 500. In this ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...

NEW YORK : T. Rowe Price Investment Management, one of Autodesk's biggest investors, plans to vote for activist investor Starboard Value's director nominees in a boardroom challenge at the ...

UNITED STATES – Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The ...

Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group. The company said on Monday that it would stop ...

Get the next trade alert free. Pfizer Inc. PFE is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...